TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04981509: Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Sponsor: National Cancer Institute (NCI) · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 65 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$2,263,800

Rescue Site Savings

+$1,478,400

Unlock Full NCT04981509 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04981509 Rescue Dossier →